Merck & Co. Inc. (MRK)

$ 129.48
   
  • Change Today:
    $0.11
  • 52 Week High: $131.95
  • 52 Week Low: $100.18
  • Currency: US Dollars
  • Shares Issued: 2,531.63m
  • Volume: 7,338,462
  • Market Cap: $327,796m
  • RiskGrade: 92

AstraZeneca's breast cancer drug moves to early primary analysis

By Frank Prenesti

Date: Wednesday 17 Feb 2021

LONDON (ShareCast) - (Sharecast News) - AstraZeneca said the phase 3 trial for breast cancer drug Lynparza would move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).




The change comes after the IDMC concluded Lynparza crossed the superiority boundary for its primary endpoint of invasive disease-free survival versus placebo for patients, and recommended primary analysis now take place, AstraZeneca said on Wednesday.

Lynparza is being jointly developed and commercialised by AstraZeneca and Merck and has been used to treat more than 40,000 patients worldwide.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Merck Market Data

Currency US Dollars
Share Price $ 129.48
Change Today $ 0.11
% Change 0.09 %
52 Week High $131.95
52 Week Low $100.18
Volume 7,338,462
Shares Issued 2,531.63m
Market Cap $327,796m
RiskGrade 92

What The Brokers Say

Strong Buy 11
Buy 12
Neutral 3
Sell 0
Strong Sell 0
Total 26
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 14-Jun-2024

Time Volume / Share Price
16:00 1,212,507 @ $129.48
15:59 200 @ $129.48
15:59 500 @ $129.48
15:59 200 @ $129.48
15:59 100 @ $129.50

Top of Page